Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $52.33

Omnicell, Inc. (NASDAQ:OMCL) has earned a consensus recommendation of “Hold” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $52.33.

A number of equities research analysts recently commented on OMCL shares. Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company lowered their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Bank of America cut their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Craig Hallum upped their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Barclays raised their price target on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $39.72 on Monday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 147.12, a price-to-earnings-growth ratio of 7.62 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The business’s 50 day simple moving average is $43.09 and its 200-day simple moving average is $43.85. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Several large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its holdings in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after buying an additional 273 shares during the period. Johnson Financial Group Inc. purchased a new position in shares of Omnicell during the 4th quarter worth about $37,000. Van ECK Associates Corp boosted its position in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Omnicell in the fourth quarter valued at approximately $53,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.